Terug
Ook genoteerd als
ESLOF
OTC
Dagbereik
€ 111,65
€ 114,70
52-Weeksbereik
€ 111,22
€ 186,81
Volume
10.952
50D / 200D Gem.
€ 142,44
/
€ 155,10
Vorige Slotkoers
€ 112,00
Koershistorie
Financiële Trends
Sectorvergelijking
vs Healthcare sector mediaan (626 peers)
| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | 46,7 | 0,4 |
| P/B | 2,7 | 2,9 |
| ROE % | 5,6 | 3,7 |
| Net Margin % | 8,1 | 3,9 |
| Rev Growth 5Y % | 8,4 | 10,0 |
| D/E | 0,4 | 0,2 |
Koersdoel Analisten
Geen analistendekking beschikbaar
Winstschattingen
| Periode | WPA Sch. | Omzet Sch. | Analisten |
|---|---|---|---|
| FY2030 |
€ 5,28
€ 5,12 – € 5,37
|
44 B | 1 |
| FY2029 |
€ 5,32
€ 5,16 – € 5,41
|
41 B | 1 |
| FY2028 |
€ 4,82
€ 4,67 – € 4,91
|
38 B | 1 |
Belangrijkste Punten
Revenue grew 8,40% annually over 5 years — modest growth
Debt/Equity of 0,44 — conservative balance sheet
Generating 3,62B in free cash flow
P/E of 46,67 — premium valuation
Revenue growth is decelerating — 1Y growth trails 5Y average by 5,16%
Cash machine — converts 162,68% of earnings into free cash flow
Groei
Revenue Growth (5Y)
8,40%
Revenue (1Y)3,24%
Earnings (1Y)-5,74%
FCF Growth (3Y)4,23%
Kwaliteit
Return on Equity
5,61%
ROIC4,33%
Net Margin8,13%
Op. Margin11,80%
Veiligheid
Debt / Equity
0,44
Current Ratio0,99
Interest Coverage14,06
Waardering
P/E Ratio
46,67
P/B Ratio2,67
EV/EBITDA36,33
Dividend Yield0,00%
All Fundamental Metrics
| Growth | |||
| Revenue Growth (1Y) | 3,24% | Revenue Growth (3Y) | 3,81% |
| Earnings Growth (1Y) | -5,74% | Earnings Growth (3Y) | -1,44% |
| Revenue Growth (5Y) | 8,40% | Earnings Growth (5Y) | 11,32% |
| Profitability | |||
| Revenue (TTM) | 27,37B | Net Income (TTM) | 2,22B |
| ROE | 5,61% | ROA | 3,48% |
| Gross Margin | 60,56% | Operating Margin | 11,80% |
| Net Margin | 8,13% | Free Cash Flow (TTM) | 3,62B |
| ROIC | 4,33% | FCF Growth (3Y) | 4,23% |
| Safety | |||
| Debt / Equity | 0,44 | Current Ratio | 0,99 |
| Interest Coverage | 14,06 | Dividend Yield | 0,00% |
| Valuation | |||
| P/E Ratio | 46,67 | P/B Ratio | 2,67 |
| P/S Ratio | 3,79 | PEG Ratio | -8,27 |
| EV/EBITDA | 36,33 | Dividend Yield | 0,00% |
| Market Cap | 103,77B | Enterprise Value | 117,27B |
Income Statement
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | 27,37B | 26,51B | 25,40B | 24,49B | 19,82B |
| Net Income | 2,22B | 2,36B | 2,29B | 2,15B | 1,45B |
| EPS (Diluted) | 2,39 | 2,57 | 2,54 | 2,42 | 1,63 |
| Gross Profit | 16,57B | 16,81B | 16,05B | 15,59B | 12,28B |
| Operating Income | 3,23B | 3,45B | 3,18B | 3,26B | 2,31B |
Balance Sheet
Annual, most recent first
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 63,87B | 64,26B | 60,52B | 60,56B | 59,42B |
| Total Liabilities | 24,39B | 23,26B | 21,63B | 22,41B | 23,54B |
| Shareholders' Equity | 38,87B | 40,38B | 38,24B | 37,46B | 35,06B |
| Total Debt | 17,04B | 13,22B | 11,66B | 12,20B | 13,02B |
| Cash & Equivalents | 3,54B | 2,25B | 2,56B | 1,76B | 1,59B |
| Current Assets | 12,00B | 10,04B | 9,72B | 8,64B | 9,28B |
| Current Liabilities | 12,15B | 10,56B | 9,74B | 8,89B | 8,93B |